[The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology]

A M Granov; L A Tiushin; M S Tlostanova; N A Kostenikov; D V Ryzhkova; V E Savello; A A Stanzhevskiĭ

[The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology]

Vopr Onkol. 2003;49(5):563-73.

[Article in Russian]

Authors

A M Granov¹, L A Tiushin, M S Tlostanova, N A Kostenikov, D V Ryzhkova, V E Savello, A A Stanzhevskiĭ

Affiliation

¹ Central Research Institute of Roentgeno-Radiology, Ministry of Health of the RF, St. Petersburg.

PMID: 14682126

Abstract

The study was concerned with evaluation of the diagnostic potential of positron emission tomography (PET) with 18-FDG in clinical oncology and elucidation of its role in assessing therapy effectiveness. The Ecat Exact 47 and Ecat Exat HR+ (Siemens) insatllations were used to examine 674 patients, with Whole Body protocol used in 585. PET with 18-FDG proved highly effective in diagnosing malignancies of the breast, lung, liver, pancreas, testis, brain and lymphoma as well as evaluating the efficacy of therapy.

Publication types

Evaluation Study

MeSH terms

Brain Neoplasms / diagnostic imaging
Breast Neoplasms / diagnostic imaging
Carbon Radioisotopes
Diagnosis, Differential
Female
Fluorodeoxyglucose F18*
Humans
Liver Neoplasms / diagnostic imaging
Lung Neoplasms / diagnostic imaging
Lymphoma / diagnostic imaging
Male
Medical Oncology / methods*
Neoplasms / diagnostic imaging*
Neoplasms / therapy
Outcome Assessment, Health Care
Pancreatic Neoplasms / diagnostic imaging
Radiopharmaceuticals
Sensitivity and Specificity
Testicular Neoplasms / diagnostic imaging
Tomography, Emission-Computed* / instrumentation
Tomography, Emission-Computed* / methods

Substances

Carbon Radioisotopes
Radiopharmaceuticals
Fluorodeoxyglucose F18